LMAT Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -13.47%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Accuray, Inc.'s return on equity of -60.6%.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 18.59%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 307.26%. Given that Accuray, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Accuray, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.92%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 37.62x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.45x versus 0.16x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -14.54%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 18.59%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 78.11%. Given that Alphatec Holdings, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Alphatec Holdings, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.92%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 37.62x while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.45x versus 2.81x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -316.61%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Plus Therapeutics, Inc.'s return on equity of --.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 18.59%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Plus Therapeutics, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.92%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 37.62x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.45x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of 27.59%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat ResMed, Inc.'s return on equity of 25.44%.

LeMaitre Vascular, Inc. has a consensus price target of $103.67, signalling upside risk potential of 18.59%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 9.51%. Given that LeMaitre Vascular, Inc. has higher upside potential than ResMed, Inc., analysts believe LeMaitre Vascular, Inc. is more attractive than ResMed, Inc..

LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.099%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.92%. ResMed, Inc. offers a yield of 0.83% to investors and pays a quarterly dividend of $0.60 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are smaller than ResMed, Inc. quarterly revenues of $1.4B. LeMaitre Vascular, Inc.'s net income of $17.4M is lower than ResMed, Inc.'s net income of $392.6M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 37.62x while ResMed, Inc.'s PE ratio is 26.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.45x versus 7.39x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.